Urologix Inc. (ULGX) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Urologix Inc.
Fiscal year is July-June. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 14.77M 12.57M 17.03M 16.59M 14.01M
Cost of Goods Sold (COGS) incl. D&A 6.59M 6.05M 8.74M 8.24M 8.21M
COGS excluding D&A 5.8M 5.49M 8.04M 7.56M 7.62M
Depreciation & Amortization Expense 793,000 565,000 695,000 675,000 587,000
Depreciation 769,000 541,000 372,000 401,000 360,000
Amortization of Intangibles 24,000 24,000 323,000 274,000 227,000
Gross Income 8.18M 6.52M 8.29M 8.35M 5.8M
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 10.44M 10.24M 12.61M 12.5M 9.71M
Research & Development 1.83M 2.24M 2.19M 2.27M 1.63M
Other SG&A 8.6M 8.01M 10.42M 10.23M 8.09M
Other Operating Expense 0 0 0 106,000 0
Unusual Expense 0 0 (172,000) (540,000) 3.02M
EBIT after Unusual Expense 0 0 172,000 540,000 (3.02M)
Non Operating Income/Expense 0 0 (13,000) (7,000) (1,000)
Non-Operating Interest Income - 1,000 0 0 0
Equity in Affiliates (Pretax) 0 0 - 0 -
Interest Expense 0 0 482,000 555,000 693,000
Gross Interest Expense 0 0 482,000 555,000 693,000
Interest Capitalized 0 0 0 0 0
Pretax Income (2.26M) (3.73M) (4.64M) (4.28M) (7.62M)
Income Tax (88,000) 8,000 55,000 14,000 (16,000)
Income Tax - Current Domestic (88,000) 8,000 20,000 13,000 20,000
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 35,000 1,000 (36,000)
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (2.17M) (3.73M) (4.7M) (4.29M) (7.61M)
Minority Interest Expense 0 0 0 0 0
Net Income (2.17M) (3.73M) (4.7M) (4.29M) (7.61M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (2.17M) (3.73M) (4.7M) (4.29M) (7.61M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (2.17M) (3.73M) (4.7M) (4.29M) (7.61M)
EPS (Basic) (0.15) (0.26) (0.32) (0.21) (0.36)
Basic Shares Outstanding 14.51M 14.56M 14.74M 20.7M 21.22M
EPS (Diluted) 0.00 (0.26) (0.32) (0.21) (0.36)
Diluted Shares Outstanding 14.51M 14.56M 14.74M 20.7M 21.22M
EBITDA (1.46M) (3.16M) (3.62M) (3.58M) (3.33M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Urologix Inc.
Fiscal year is July-June. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 14.77M 12.57M 17.03M 16.59M 14.01M
Cost of Goods Sold (COGS) incl. D&A 6.59M 6.05M 8.74M 8.24M 8.21M
COGS excluding D&A 5.8M 5.49M 8.04M 7.56M 7.62M
Depreciation & Amortization Expense 793,000 565,000 695,000 675,000 587,000
Depreciation 769,000 541,000 372,000 401,000 360,000
Amortization of Intangibles 24,000 24,000 323,000 274,000 227,000
Gross Income 8.18M 6.52M 8.29M 8.35M 5.8M
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 10.44M 10.24M 12.61M 12.5M 9.71M
Research & Development 1.83M 2.24M 2.19M 2.27M 1.63M
Other SG&A 8.6M 8.01M 10.42M 10.23M 8.09M
Other Operating Expense 0 0 0 106,000 0
Unusual Expense 0 0 (172,000) (540,000) 3.02M
EBIT after Unusual Expense 0 0 172,000 540,000 (3.02M)
Non Operating Income/Expense 0 0 (13,000) (7,000) (1,000)
Non-Operating Interest Income - 1,000 0 0 0
Equity in Affiliates (Pretax) 0 0 - 0 -
Interest Expense 0 0 482,000 555,000 693,000
Gross Interest Expense 0 0 482,000 555,000 693,000
Interest Capitalized 0 0 0 0 0
Pretax Income (2.26M) (3.73M) (4.64M) (4.28M) (7.62M)
Income Tax (88,000) 8,000 55,000 14,000 (16,000)
Income Tax - Current Domestic (88,000) 8,000 20,000 13,000 20,000
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 35,000 1,000 (36,000)
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (2.17M) (3.73M) (4.7M) (4.29M) (7.61M)
Minority Interest Expense 0 0 0 0 0
Net Income (2.17M) (3.73M) (4.7M) (4.29M) (7.61M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (2.17M) (3.73M) (4.7M) (4.29M) (7.61M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (2.17M) (3.73M) (4.7M) (4.29M) (7.61M)
EPS (Basic) (0.15) (0.26) (0.32) (0.21) (0.36)
Basic Shares Outstanding 14.51M 14.56M 14.74M 20.7M 21.22M
EPS (Diluted) 0.00 (0.26) (0.32) (0.21) (0.36)
Diluted Shares Outstanding 14.51M 14.56M 14.74M 20.7M 21.22M
EBITDA (1.46M) (3.16M) (3.62M) (3.58M) (3.33M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
